The European Patent Office has granted a patent no.EP1357922B1 to Avita Medical's cell platform technology.
The patent covers claims related to the preparation of a cell suspension comprised of the patient’s own epithelial cells, therapeutic use of the cell suspension and a ‘composition of matter’ claim wherein the actual suspension of autologous cells is covered.
The patented technology is incorporated into the company’s regenerative product, ReCell Spray-On Skin, used in the treatment of chronic and acute wounds and various reconstructive and aesthetic procedures.
Avita Medical CEO William Dolphin said the patent grant further validates the company’s capabilities in harnessing the body’s ability to heal itself and to regenerate damaged tissue.
"The patent secures additional protection for our intellectual property in the rapidly growing field of regenerative medicine," Dolphin added.